452 related articles for article (PubMed ID: 29967022)
21. Heteroresistance to Piperacillin-Tazobactam in Clinical Isolates of Escherichia coli Sequence Type 131.
Rodríguez-Villodres Á; Ortiz de la Rosa JM; Álvarez-Marín R; Pachón J; Aznar J; Lepe JA; Smani Y
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061749
[No Abstract] [Full Text] [Related]
22. Evaluation of studies on extended versus standard infusion of beta-lactam antibiotics.
Chen M; Buurma V; Shah M; Fahim G
Am J Health Syst Pharm; 2019 Sep; 76(18):1383-1394. PubMed ID: 31505562
[TBL] [Abstract][Full Text] [Related]
23. A Large-Scale Multicenter Retrospective Study on Nephrotoxicity Associated With Empiric Broad-Spectrum Antibiotics in Critically Ill Patients.
Chen AY; Deng CY; Calvachi-Prieto P; Armengol de la Hoz MÁ; Khazi-Syed A; Chen C; Scurlock C; Becker CD; Johnson AEW; Celi LA; Dagan A
Chest; 2023 Aug; 164(2):355-368. PubMed ID: 37040818
[TBL] [Abstract][Full Text] [Related]
24. In silico evaluation of a beta-lactam dosing guideline among adults with serious infections.
Williams P; Cotta MO; Abdul-Aziz MH; Wilks K; Farkas A; Roberts JA
Pharmacotherapy; 2023 Nov; 43(11):1121-1130. PubMed ID: 36567467
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the Nephrotoxicity of Vancomycin in Combination With Cefepime, Meropenem, or Piperacillin/Tazobactam: A Prospective, Multicenter Study.
Mullins BP; Kramer CJ; Bartel BJ; Catlin JS; Gilder RE
Ann Pharmacother; 2018 Jul; 52(7):639-644. PubMed ID: 29442542
[TBL] [Abstract][Full Text] [Related]
26. Antimicrobial activity of high-dose cefepime-tazobactam (WCK 4282) against a large collection of gram-negative organisms collected worldwide in 2018 and 2019.
Sader HS; Carvalhaes CG; Mendes RE; Castanheira M
Int J Infect Dis; 2022 Mar; 116():306-312. PubMed ID: 35066163
[TBL] [Abstract][Full Text] [Related]
27. Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?
Udy AA; Lipman J; Jarrett P; Klein K; Wallis SC; Patel K; Kirkpatrick CM; Kruger PS; Paterson DL; Roberts MS; Roberts JA
Crit Care; 2015 Jan; 19(1):28. PubMed ID: 25632974
[TBL] [Abstract][Full Text] [Related]
28. Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam, Cefepime, or Meropenem.
Blevins AM; Lashinsky JN; McCammon C; Kollef M; Micek S; Juang P
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30782987
[TBL] [Abstract][Full Text] [Related]
29. Piperacillin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis.
Kanji S; Roberts JA; Xie J; Alobaid A; Zelenitsky S; Hiremath S; Zhang G; Watpool I; Porteous R; Patel R
Ann Pharmacother; 2018 Oct; 52(10):965-973. PubMed ID: 29730948
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience.
Richter DC; Frey O; Röhr A; Roberts JA; Köberer A; Fuchs T; Papadimas N; Heinzel-Gutenbrunner M; Brenner T; Lichtenstern C; Weigand MA; Brinkmann A
Infection; 2019 Dec; 47(6):1001-1011. PubMed ID: 31473974
[TBL] [Abstract][Full Text] [Related]
31. Population Pharmacokinetics of Piperacillin following Continuous Infusion in Critically Ill Patients and Impact of Renal Function on Target Attainment.
Klastrup V; Thorsted A; Storgaard M; Christensen S; Friberg LE; Öbrink-Hansen K
Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32284376
[TBL] [Abstract][Full Text] [Related]
32. Vancomycin with concomitant piperacillin/tazobactam vs. cefepime or meropenem associated acute kidney injury in the critically ill: A multicenter propensity score-matched study.
Buckley MS; Komerdelj IA; D'Alessio PA; Rangan P; Agarwal SK; Tinta NC; Martinez BK; Ziadat DS; Yerondopoulos MJ; Kobic E; Kane-Gill SL
J Crit Care; 2022 Feb; 67():134-140. PubMed ID: 34768175
[TBL] [Abstract][Full Text] [Related]
33. A Monte Carlo Simulation Approach for Beta-Lactam Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy.
Jang SM; Gharibian KN; Lewis SJ; Fissell WH; Tolwani AJ; Mueller BA
J Clin Pharmacol; 2018 Oct; 58(10):1254-1265. PubMed ID: 29746711
[TBL] [Abstract][Full Text] [Related]
34. β-Lactam Dosage Regimens in Septic Patients with Augmented Renal Clearance.
Jacobs A; Taccone FS; Roberts JA; Jacobs F; Cotton F; Wolff F; Creteur J; Vincent JL; Hites M
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29987138
[TBL] [Abstract][Full Text] [Related]
35. Comparative Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam or Cefepime: A Retrospective Cohort Study.
Hammond DA; Smith MN; Painter JT; Meena NK; Lusardi K
Pharmacotherapy; 2016 May; 36(5):463-71. PubMed ID: 26952639
[TBL] [Abstract][Full Text] [Related]
36. [The reliability of using impenem, meropenem, cefoperazone-sulbactam and piperacillin-tazobactam to treat nosocomial Gram-negative bacterial infections with Monte Carlo simulation].
Xiao YH; Hu YJ
Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):595-600. PubMed ID: 28789493
[No Abstract] [Full Text] [Related]
37. Usefulness of therapeutic drug monitoring of piperacillin and meropenem in routine clinical practice: a prospective cohort study in critically ill patients.
Schoenenberger-Arnaiz JA; Ahmad-Diaz F; Miralbes-Torner M; Aragones-Eroles A; Cano-Marron M; Palomar-Martinez M
Eur J Hosp Pharm; 2020 Mar; 27(e1):e30-e35. PubMed ID: 32296502
[TBL] [Abstract][Full Text] [Related]
38. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program.
Ong CT; Kuti JL; Nicolau DP;
Surg Infect (Larchmt); 2005; 6(4):419-26. PubMed ID: 16433606
[TBL] [Abstract][Full Text] [Related]
39. Could an Optimized Joint Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam Be a Valuable Innovative Approach for Maximizing the Effectiveness of Monotherapy Even in the Treatment of Critically Ill Patients with Documented Extended-Spectrum Beta-Lactamase-Producing
Gatti M; Rinaldi M; Tonetti T; Siniscalchi A; Viale P; Pea F
Antibiotics (Basel); 2023 Dec; 12(12):. PubMed ID: 38136770
[TBL] [Abstract][Full Text] [Related]
40. Early target attainment of continuous infusion piperacillin/tazobactam and meropenem in critically ill patients: A prospective observational study.
Dhaese SAM; Thooft ADJ; Farkas A; Lipman J; Verstraete AG; Stove V; Roberts JA; De Waele JJ
J Crit Care; 2019 Aug; 52():75-79. PubMed ID: 30986758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
